Vitadao launches biotech company to fight aging with naked mole-rats

A decentralized independent organization (Dao) He is taking his passion for life extension by founding a biotech company to pursue cutting-edge science in the treatment of cancer and other age-related diseases.

Vitadaoannounced the launch of Matrix Biosciences in partnership with world-renowned biologist Vera Gorbunova, a community-owned cooperative with a mission to fund and advance first-rate long-term research. Professor Gorbunova of the University of Rochester was recognized for his distinction. Anticancer properties in the nude mole-rat.

Todd White, a core member of VitaDao, told Decrypt that the idea behind the new company was t.o “Bringing research out of the DAO into the real world” instead of keeping it on-chain.

Unlike VitaDAO's decentralized nature, White explained, Matrix Bioscience is centralized and operates like a traditional company. In reality, the majority shareholder will be Vitadao, and the newly created biotech will be required to provide them with quarterly reports – similar to conventional investment structures.

“We want to show that blockchain can effectively coexist with the biotech industry,” he said.

Acknowledging the tight legal environment of medicine and healthcare, both VitaDAO and the newly formed Matrix Biosciences said they are working “proactively” with regulators. There is a real reputational risk associated with the crypto industry, so you want to make sure that “we are not cows”.

Matrix Bioscience's mission is bleeding edge, Eleanor Davis added, adding that a Principal member The VitaDAO. She told him Decrypt The company has announced that it will use its long-lasting mole-rat in mice for long-term research. The compound is anti-cancer, anti-pain and longevity-promoting in these rodent species.

Matrix Biosciences wants to use its properties to develop applications for the treatment of cancer and other age-related diseases in humans, a strategy Davis said. It aligns with VitaDAO's mission.

“Our funding mandate is to fund ‘lunar bleeding-edge research' that is often not eligible. [National Institutes of Health] Or traditional venture capital,” she said. For her, Matrix Bioscience works to create “the next blockbuster therapeutic.”

Both White and Davis described the work of Gorbunova, who serves as Matrix Bioscience's lead scientist. And she has been working for many years in longevity, genome stability and long-lived mammalian systems. She is currently Associate Director of the University of Rochester Geriatrics Research Center and has received many awards for her research over the years.

VitaDao—which counts Pfizer Ventures among its contributors—will initially back Matrix Biosciences with $300,000. Later, the enterprise will be allocated additional capital through the IP-NFT fractional model.

Today's graduation is “a great signal to the biotech community that we are not fooled,” White said.